MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as “Orphan Drug”
MUNSTER,
announced that they have filed on
indication treatment-relevant levodopa-induced dyskinesia in Parkinson’s
disease for orphan drug status designation with the European Medicines Agency
(EMEA). Levodopa-induced dyskinesia is a complication of the mainstay
treatment in advanced Parkinson’s and a serious burden to some of those
affected, since it may be disabling for the patients and preventing them from
receiving optimal treatment for Parkinson’s.
Flibanserin is a 5-HT1a agonist and a 5-HT2a antagonist and thus fits in
with the current theory on levodopa-induced dysinesia that dyskinesia is
caused by the release of dopamine from serotonergic neurons. MONITORING FORCE
is preparing to file another orphan drug status application with the United
States Food and Drug Administration (FDA) and expects the first clinical
trial in Parkinson’s patients to start by mid-2010.
MONITORING FORCE GmbH is a clinical research company based in
Munster/
countries. MONITORING FORCE does contract research for the pharmaceutical
industry as well as re-purposing drug development projects on their own.
MONITORING FORCE has been founded in
countries since. Parkinson’s disease is a primary focus of the company.
Contact (Company): Dr. Jurgen Beck
General Manager, MONITORING FORCE GmbH
Bahnhofstrasse 111, 48143 Munster, Germany
Tel.: +49-251-214-01-30, +49-251-26-39-577 (DD)
Fax: +49-251-21-401-53-9, Mobile: +49-171-869-82-40
beck@monitoring-force.com, http://www.monitoring-force.eu
Contact (Media): Aysun Ertan
Project Manager, Targa Communications
Goethestrasse 22, 60313 Frankfurt am Main, Germany
Tel.: +49-69-66-36-83-98, Fax: +49-69-66-36-83-99
ae@targacommunications.de, http://www.targacommunications.de
SOURCE MONITORING FORCE GmbH